Progressive Insider Andrew Quigg Sells 1,649 Shares at $204.35; Analysts Cut Targets to $275, $261, $239
On January 21, insider Andrew Quigg sold 1,649 Progressive shares at $204.35, reducing his stake to 39,626 shares. JPMorgan cut its price target from $303 to $275, UBS lowered theirs to $261 and BMO to $239, leaving a consensus target of $259.39 with a Hold rating.
1. Insider Sale Details
On January 21st, Andrew Quigg, Senior Vice President of The Progressive Corporation, disposed of 1,649 shares in a Form 4 filing with the SEC. The shares were sold at an average of $204.35 per share, generating proceeds of $336,973.15. Following the transaction, Quigg’s holdings decreased by 4.0%, leaving him with 39,626 shares, valued at approximately $8.1 million.
2. Dividend Declaration and Payout Metrics
The company declared a quarterly dividend of $0.10 per share, paid on January 8th to shareholders of record as of January 2nd. This distribution represents an annualized dividend of $0.40 per share and yields 0.2% on an annual basis. The dividend payout ratio stands at 2.19%, underscoring management’s conservative capital allocation policy relative to underwriting and investment income.
3. Institutional Position Shifts
During the third quarter, several large institutional investors adjusted their stakes. Vanguard Group added 151,240 shares to reach 54.7 million shares, State Street increased by 78,374 shares to 25.8 million, and Capital International Investors made the most significant move by purchasing 6.0 million additional shares, bringing its total to 13.7 million. Geode Capital Management boosted its holding by 301,371 shares to 15.5 million, while Capital Research Global Investors added 2.3 million shares, totaling 11.2 million. Collectively, these five firms now account for over 60% of the float, reflecting strong confidence at the institutional level.
4. Recent Analyst Rating Adjustments
In January, BMO Capital Markets revised its rating from outperform to market perform and lowered its target to reflect moderating premium growth expectations. Earlier in the quarter, JPMorgan Chase trimmed its price target and maintained an overweight designation, while William Blair moved to market perform. Morgan Stanley continues to carry an underweight stance, and UBS maintains a neutral rating after a slight target reduction. Of 22 analysts tracked by MarketBeat, seven rate the stock as buy, thirteen as hold and two as sell, producing a consensus hold recommendation.